Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Potential Cures of Alzheimer's Dementia
share announcement

Potential Cures of Alzheimer's Dementia

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Mental Health".

Deadline for manuscript submissions: 10 May 2025 | Viewed by 5296

Special Issue Editor

Prof. Dr. Jeffrey Fessel

E-Mail Website
Guest Editor
Department of Medicine, University of California, 2069 Filbert Street, San Francisco, CA 94123, USA
Interests: Alzheimer’s dementia; schizophrenia; long COVID and mental symptoms; HIV/AIDS; rheumatic disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Several thousand reports detail information concerning potential causes of Alzheimer’s dementia (AD). Surely, a cure for this form of dementia must be attainable, which is why a Special Issue of the Journal of Clinical Medicine invites articles showing potential cures. Curing any medical condition has two generic approaches. The first treats all of the possible causes that contribute to pathogenesis; this requires dozens of drugs. AD may have >15 possible causes requiring >30 drugs, which could be administered sequentially in small numbers over a long period of time. Most of the few articles published about curing AD have proposed that approach. However, AD clearly has multiple causes, and these may differ from patient to patient, so a ‘one size fits all’ approach might be incorrect. A second approach avoids this by identifying, for each separate patient, only those components of pathogenesis that are actually operative. Articles using either approach are welcome.

Dr. Jeffrey Fessel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Alzheimer’s dementia
  • cure
  • therapeutic approaches
  • clinical assessment
  • diagnosis
  • treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 294 KiB  
Article
Role of Overload and Psychoemotional Variables on Health-Related Quality of Life in Informal Caregivers of People with Alzheimer’s Disease
by Patricia Ferrero-Sereno, Patricia Palomo-López, María Mendoza-Muñoz, Jorge Carlos-Vivas, Javier Urbano-Mairena and Laura Muñoz-Bermejo
J. Clin. Med. 2024, 13(20), 6188; https://doi.org/10.3390/jcm13206188 - 17 Oct 2024
Viewed by 571
Abstract
Background: Carers of people with Alzheimer’s disease often have a high degree of commitment and dedication which may also compromise physical and emotional, leisure, and occupational self-care. This study aimed to explore health-related quality of life (HRQoL) and psychoemotional variables in caregivers with [...] Read more.
Background: Carers of people with Alzheimer’s disease often have a high degree of commitment and dedication which may also compromise physical and emotional, leisure, and occupational self-care. This study aimed to explore health-related quality of life (HRQoL) and psychoemotional variables in caregivers with and without caregiver overload and its relationship. Methods: A single-measure cross-sectional correlational study was carried out involving 59 informal caregivers of people with Alzheimer’s disease with a mean age of 59.30 (±10.58). The participants completed the adult HRQoL questionnaires (EQ-5D-3L), Zarit Burden Inventory test, General Happiness Questionnaire, Satisfaction with Life Scale, Rosenberg self-esteem scale, Occupational Balance Questionnaire (OBQ-E), International Fitness Scale (IFIS), Family Apgar scale, and Duke-UNC-11 Functional Social Support Questionnaire. Results: A significantly higher level of HRQoL (p = 0.029) in subjective happiness (p = 0.018), perceived social support (p = 0.046), avoidance (p = 0.034), occupational balance (p = 0.002), life satisfaction (p = 0.037), and self-perceived physical fitness (p = 0.021) was found in caregivers without perceived overload. Also, HRQoL was directly associated with self-perceived physical fitness (β = 0.534; p < 0.001) and occupational balance (β = 0.375; p < 0.001) and self-esteem (β = 0.249; p < 0.016). Conclusions: Caregivers who do not perceive overload have better levels of HRQoL and psychoemotional variables, establishing a relationship between HRQoL with self-perceived physical fitness, occupational balance, and self-esteem. Full article
(This article belongs to the Special Issue Potential Cures of Alzheimer's Dementia)

Review

Jump to: Research

25 pages, 723 KiB  
Review
Biomarker-Based Precision Therapy for Alzheimer’s Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine
by Anastasia Bougea and Philippos Gourzis
J. Clin. Med. 2024, 13(16), 4661; https://doi.org/10.3390/jcm13164661 - 8 Aug 2024
Viewed by 1451
Abstract
(1) Background: Alzheimer’s disease (AD) is a worldwide neurodegenerative disorder characterized by the buildup of abnormal proteins in the central nervous system and cognitive decline. Since no radical therapy exists, only symptomatic treatments alleviate symptoms temporarily. In this review, we will explore the [...] Read more.
(1) Background: Alzheimer’s disease (AD) is a worldwide neurodegenerative disorder characterized by the buildup of abnormal proteins in the central nervous system and cognitive decline. Since no radical therapy exists, only symptomatic treatments alleviate symptoms temporarily. In this review, we will explore the latest advancements in precision medicine and biomarkers for AD, including their potential to revolutionize the way we diagnose and treat this devastating condition. (2) Methods: A literature search was performed combining the following Medical Subject Heading (MeSH) terms on PubMed: “Alzheimer’s disease”, “biomarkers”, “APOE”, “APP”, “GWAS”, “cerebrospinal fluid”, “polygenic risk score”, “Aβ42”, “τP-181”, “ p-tau217”, “ptau231”, “proteomics”, “total tau protein”, and “precision medicine” using Boolean operators. (3) Results: Genome-wide association studies (GWAS) have identified numerous genetic variants associated with AD risk, while a transcriptomic analysis has revealed dysregulated gene expression patterns in the brains of individuals with AD. The proteomic and metabolomic profiling of biological fluids, such as blood, urine, and CSF, and neuroimaging biomarkers have also yielded potential biomarkers of AD that could be used for the early diagnosis and monitoring of disease progression. (4) Conclusion: By leveraging a combination of the above biomarkers, novel ultrasensitive immunoassays, mass spectrometry methods, and metabolomics, researchers are making significant strides towards personalized healthcare for individuals with AD. Full article
(This article belongs to the Special Issue Potential Cures of Alzheimer's Dementia)
►▼ Show Figures

Figure 1

9 pages, 252 KiB  
Review
All GLP-1 Agonists Should, Theoretically, Cure Alzheimer’s Dementia but Dulaglutide Might Be More Effective Than the Others
by Jeffrey Fessel
J. Clin. Med. 2024, 13(13), 3729; https://doi.org/10.3390/jcm13133729 - 26 Jun 2024
Viewed by 2838
Abstract
Addressing the dysfunctions of all brain cell types in Alzheimer’s disease (AD) should cure the dementia, an objective that might be achieved by GLP-1 agonist drugs, because receptors for GLP-1 are present in all of the main brain cell types, i.e., neurons, oligodendroglia, [...] Read more.
Addressing the dysfunctions of all brain cell types in Alzheimer’s disease (AD) should cure the dementia, an objective that might be achieved by GLP-1 agonist drugs, because receptors for GLP-1 are present in all of the main brain cell types, i.e., neurons, oligodendroglia, astroglia, microglia, endothelial cells and pericytes. This article describes the benefits provided to all of those brain cell types by GLP-1 agonist drugs. The article uses studies in humans, not rodents, to describe the effect of GLP-1 agonists upon cognition, because rodents’ brains differ from those of humans in so many ways that results from rodent studies may not be totally transferable to humans. Commercially available GLP-1 agonists have mostly shown either positive effects upon cognition or no effects. One important reason for no effects is a reduced rate of entering brain parenchyma. Dulaglutide has the greatest entry to brain, at 61.8%, among the available GLP-1 agonists, and seems to offer the best likelihood for cure of AD. Although there is only one study of cognition that used dulaglutide, it was randomized, placebo controlled, and very large; it involved 8828 participants and showed significant benefit to cognition. A clinical trial to test the hypothesis that dulaglutide may cure AD should have, as its primary outcome, a 30% greater cure rate of AD by dulaglutide than that achieved by an equipoise arm of, e.g., lithium plus memantine. Full article
(This article belongs to the Special Issue Potential Cures of Alzheimer's Dementia)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop